NKTR
Nektar Therapeutics
$65.56
-$1.05(-1.58%)
44
Overall
40
Value
50
Tech
42
Quality
Market Cap
$1.20B
Volume
848.96K
52W Range
$7.99 - $109.00
Target Price
$153.25
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $165.4M | $307.7M | $1.2B | $114.6M | $152.9M | $93.9M | $92.1M | $90.1M | $98.4M | $55.2M | ||
| Total Revenue | $55.4M | $307.7M | $1.2B | $114.6M | $152.9M | $101.9M | $92.1M | $90.1M | $98.4M | $55.2M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-30.2M | $-30.5M | $-24.4M | $21.4M | $19.5M | $24.9M | $21.6M | $33.8M | $30.7M | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $135.2M | $261.2M | $1.2B | $93.2M | $133.4M | $77.0M | $70.4M | $56.4M | $67.7M | $55.2M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $248.1M | $320.8M | $481.0M | $533.3M | $513.4M | $523.1M | $310.7M | $191.6M | $197.7M | $186.0M | ||
| Research & Development | $203.8M | $268.5M | $399.5M | $434.6M | $408.7M | $400.3M | $218.3M | $114.2M | $120.9M | $117.3M | ||
| Research Expense | $203.8M | $268.5M | $399.5M | $434.6M | $408.7M | $400.3M | $218.3M | $114.2M | $120.9M | $117.3M | ||
| Selling, General & Administrative | $44.3M | $52.4M | $81.4M | $98.7M | $104.7M | $122.8M | $92.3M | $77.4M | $76.8M | $68.7M | ||
| General & Administrative Expenses | $44.3M | $52.4M | $81.4M | $98.7M | $104.7M | $122.8M | $92.3M | $77.4M | $76.8M | $68.7M | ||
| Salaries & Wages | $-25.9M | $-36.6M | $-88.1M | -- | -- | -- | -- | $33.4M | -- | -- | ||
| Depreciation & Amortization | $-13.2M | $-12.6M | $-8.8M | $11.0M | $12.5M | $13.0M | $12.2M | $7.8M | $4.4M | -- | ||
| Depreciation & Amortization | $-13.2M | $-12.6M | $-8.8M | $11.0M | $12.5M | $13.0M | $12.2M | $7.8M | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | -- | $78.6M | $1.6M | -- | -- | ||
| Other Operating Expenses | -- | -- | $-8.0M | $-49.9M | $-2.5M | $-2.4M | $-378.0K | $-848.0K | $203.6M | $195.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-112.9M | $-59.6M | $687.9M | $-440.0M | $-425.1M | $-446.1M | $-376.2M | $-263.7M | $-105.2M | $-140.1M | ||
| EBITDA | $-135.4M | $-79.4M | $715.2M | $-405.6M | $-392.6M | $-461.8M | $-323.0M | $-283.3M | $-124.1M | $-168.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $22.5M | $22.1M | $21.6M | $21.3M | $37.1M | $47.3M | $28.9M | $25.3M | $28.1M | -- | ||
| Intinc | $-19.7M | $-18.9M | $-21.2M | -- | -- | -- | $6.8M | $19.0M | $14.5M | $10.4M | ||
| Net Non-Operating Interest Income/Expense | $-42.2M | $-41.0M | $-42.8M | $-21.3M | $-6.9M | -- | $22.1M | $19.0M | $14.5M | $10.4M | ||
| Gain on Sale of Securities | $79.0K | $-533.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-2.4M | $-4.5M | $-37.6M | $-21.3M | $12.0M | $69.2M | $-102.6M | $6.2M | $390.0K | $8.4M | ||
| Other Special Charges | $2.4M | $4.5M | $37.6M | $21.3M | $-12.0M | $-69.2M | $4.4M | $-6.2M | $-390.0K | $361.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $135.9M | $52.0M | $15.7M | $9.3M | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-135.9M | $-128.5M | $-15.7M | $-9.3M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | $65.8M | $76.5M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-150.8M | $-94.1M | $704.3M | $-418.7M | $-406.8M | $-476.0M | $-336.1M | $-276.3M | $-119.2M | $-164.2M | ||
| Pre-Tax Income | $-152.6M | $-96.1M | $682.7M | $-440.1M | $-443.9M | $-523.3M | $-365.0M | $-276.3M | $-119.2M | $-155.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $876.0K | $616.0K | $1.4M | $613.0K | $493.0K | $557.0K | $3.2M | $-200.0K | $-239.0K | $-138.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-153.5M | $-96.7M | $681.3M | $-440.7M | $-444.4M | $-523.8M | $-368.2M | $-276.1M | $-119.0M | $-164.1M | ||
| Net Income (Continuing Operations) | $-153.5M | $-96.7M | $681.3M | $-440.7M | $-444.4M | $-523.8M | $-368.2M | $-276.1M | $-119.0M | $-164.1M | ||
| Net Income (Discontinued Operations) | $-153.5M | $-96.7M | $681.3M | $-440.7M | $-444.4M | $-523.8M | $-368.2M | $-276.1M | $-119.0M | $-164.1M | ||
| Net Income (Common Stockholders) | $-153.5M | $-96.7M | $681.3M | $-440.7M | $-444.4M | $-523.8M | $-368.2M | $-276.1M | $-119.0M | $-137.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-141.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $217.9M | $290.3M | $456.6M | $554.7M | $532.8M | $548.0M | $332.3M | $225.3M | $228.3M | $186.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $9.3M | $10.4M | $11.3M | $11.7M | $11.9M | $12.2M | $12.5M | $12.7M | $13.7M | $16.9M | ||
| Average Shares Outstanding (Diluted) | $9.3M | $10.4M | $12.0M | $11.7M | $11.9M | $12.2M | $12.5M | $12.7M | $13.7M | $16.9M | ||
| Shares Outstanding | $12.5M | $12.5M | $12.5M | $12.5M | $12.5M | $12.5M | $12.6M | $33.8M | $12.4M | $28.7M | ||
| Basic EPS | $-4.2 | $-3.15 | $60.3 | $-37.8 | $-37.35 | $-42.9 | $-29.55 | $-21.75 | $-8.7 | $-9.73 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-37.8 | $-37.35 | $-42.9 | $-29.55 | $-21.75 | $-8.7 | $-9.73 | ||
| Diluted EPS | $-16.5 | $-9.3 | $56.7 | $-37.8 | $-37.35 | $-42.9 | $-29.55 | $-21.75 | $-8.7 | $-9.73 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-37.8 | $-37.35 | $-42.9 | $-29.55 | $-21.75 | $-8.7 | $-9.73 | ||
| OTHER METRICS | ||||||||||||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-8.7M | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-8.7M | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | -- | -- | $40.4M | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | $-8.0M | $3.3M | $-1.3M | -- | -- | ||
| Interest Expense Operating | $-20.6M | $-20.1M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $44.3M | $52.4M | $81.4M | $98.7M | $104.7M | $122.8M | $92.3M | $77.4M | $76.8M | $68.7M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | $67.9M | $35.3M | $8.3M | $4.4M | ||
| Rent And Landing Fees | $44.3M | $52.4M | $81.4M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $135.9M | $52.0M | $15.7M | $9.3M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NKTR | $65.56 | -1.6% | 848.96K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |